Research Progress of CAR-T Therapy in Tumor Therapy
- 10.2991/978-2-494069-31-2_7How to use a DOI?
- CAR-T therapy; tumor; CAR construction; targets; problems and solutions
New progress is constantly being made in the field of tumor treatment, and new advances are constantly being made. Among them, chimeric antigen receptor T cell (CAR-T) immunotherapy is a gene therapy method that expresses transmembrane chimeric antigen receptors by gene editing and redirects T cells to recognize tumor cells specifically. CAR-T cells can kill tumor cells effectively so as to achieve the aim of treating malignant tumors. This is a highly promising approach to cancer immunotherapy that is precise, rapid, efficient, and has the potential to cure cancer. This paper summarizes the development course and research progress of CAR-T therapy and illustrates important targets of CAR-T cells in tumor treatment, such as CD19, prostate specific membrane antigen, human epidermal growth factor receptor-2, etc. Meanwhile, the paper presents the current problems facing CAR-T cell immunotherapy, such as the toxicity of CAR-T therapy, the exhaustion of CAR-T cells and their safety, as well as the corresponding effective solutions. The paper will use tumor specific antigen as a target or design double target CAR-T cells to deal with off-target toxicity. Besides, it regulates CAR-T cell activity in vivo to reduce CRS. The results indicate that blocking checkpoints or inhibiting exhaustion-related transcription factors can resist exhaustion. Further process optimization can improve the carrier's safety.
- © 2022 The Author(s)
- Open Access
- Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
Cite this article
TY - CONF AU - Jingyu Zhao PY - 2022 DA - 2022/12/29 TI - Research Progress of CAR-T Therapy in Tumor Therapy BT - Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022) PB - Atlantis Press SP - 49 EP - 58 SN - 2352-5398 UR - https://doi.org/10.2991/978-2-494069-31-2_7 DO - 10.2991/978-2-494069-31-2_7 ID - Zhao2022 ER -